C57BL/6NCya-Cdk12em1flox/Cya
Common Name
Cdk12-flox
Product ID
S-CKO-14426
Backgroud
C57BL/6NCya
Strain ID
CKOCMP-69131-Cdk12-B6N-VA
When using this mouse strain in a publication, please cite “Cdk12-flox Mouse (Catalog S-CKO-14426) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Cdk12-flox
Strain ID
CKOCMP-69131-Cdk12-B6N-VA
Gene Name
Product ID
S-CKO-14426
Gene Alias
1810022J16Rik, Crk7, Crkrs, D11Ertd752e, Pksc
Background
C57BL/6NCya
NCBI ID
Modification
Conditional knockout
Chromosome
Chr 11
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000107538
NCBI RefSeq
NM_001109626
Target Region
Exon 4
Size of Effective Region
~1.8 kb
Overview of Gene Research
Cyclin-dependent kinase 12 (Cdk12) is a member of the CDK family, which is crucial for various cellular processes. It engages in transcription, post-transcriptional modification, cell cycle, translation, and cellular proliferation. Cdk12 also regulates the expression of cancer-related genes involved in the DNA-damage response (DDR) and replication, maintaining genomic stability [1,3,4,5].
In prostate cancer, biallelic loss of Cdk12 defines a metastatic castration-resistant prostate cancer (mCRPC) subtype. Ablation of Cdk12 in murine prostate epithelium can induce preneoplastic lesions with lymphocytic infiltration. Cdk12 inactivation mediates genomic instability by inducing transcription-replication conflicts. Moreover, Cdk12-mutant organoids and patient-derived xenografts are sensitive to inhibition or degradation of the paralog kinase, Cdk13 [2,6].
In conclusion, Cdk12 is essential for multiple cellular functions, especially in maintaining genomic stability through regulating DDR and replication-related genes. Studies using gene knockout models in mice have revealed its role in prostate cancer progression, highlighting its potential as a therapeutic target for this disease.
References：
1. Emadi, Fatemeh, Teo, Theodosia, Rahaman, Muhammed H, Wang, Shudong. 2020. CDK12: a potential therapeutic target in cancer. In Drug discovery today, 25, 2257-2267. doi:10.1016/j.drudis.2020.09.035. https://pubmed.ncbi.nlm.nih.gov/33038524/
2. Wu, Yi-Mi, Cieślik, Marcin, Lonigro, Robert J, Robinson, Dan R, Chinnaiyan, Arul M. . Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. In Cell, 173, 1770-1782.e14. doi:10.1016/j.cell.2018.04.034. https://pubmed.ncbi.nlm.nih.gov/29906450/
3. Liu, Hui, Liu, Kangdong, Dong, Zigang. 2020. Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery. In Cancer research, 81, 18-26. doi:10.1158/0008-5472.CAN-20-2245. https://pubmed.ncbi.nlm.nih.gov/32958547/
4. Liang, Shujing, Hu, Lifang, Wu, Zixiang, Xu, Xia, Qian, Airong. 2020. CDK12: A Potent Target and Biomarker for Human Cancer Therapy. In Cells, 9, . doi:10.3390/cells9061483. https://pubmed.ncbi.nlm.nih.gov/32570740/
5. Yan, Zhijia, Du, Yongli, Zhang, Haibin, Dong, Ning, He, Fang. 2023. Research progress of anticancer drugs targeting CDK12. In RSC medicinal chemistry, 14, 1629-1644. doi:10.1039/d3md00004d. https://pubmed.ncbi.nlm.nih.gov/37731700/
6. Tien, Jean Ching-Yi, Luo, Jie, Chang, Yu, Ding, Ke, Chinnaiyan, Arul M. 2024. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. In Cell reports. Medicine, 5, 101758. doi:10.1016/j.xcrm.2024.101758. https://pubmed.ncbi.nlm.nih.gov/39368479/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.